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Abstract: 
 
The overall aim of this study is to computationally identify and analyze the nature of transcription 
factors other than androgen receptor (AR) that play an important role in the regulation of gene 
expression and the subsequent progression of the castrate-resistant prostate cancer (CRPC). 
Anti-androgen therapy would relapse in about 20% of the treated patients leading to the 
development of drug resistance in CRPC. This leads to the search for other transcription factors 
and cofactors as suitable drug targets other than AR that have a role in proliferation of the 
prostate cancer cells in CRPC. The study of these transcription factors could highlight a possible 
role in determining an alternative treatment approach in contrast to current methods that focus 
primarily on AR-dependent pathways. These transcription factors also have important role in the 
common prostate cancer and is not displayed much due to the more active AR signaling.  
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1. INTRODUCTION 
 
Prostate cancer is a heterogenous and clinically diagnosed malignancy in males with high 
variability through progression (Shoag & Barbieri, 2016). It is one of the most known common 
cancer and is dependent on activation and regulation of Androgen Receptor (AR).  Symptoms of 
prostate cancer include loss of weight, impotence, spinal cord depression, loss of mobility, and 
severe pain (last three symptoms are related to bone metastasis) (Hamilton, Sharp, Peters, & 
Round, 2006) (Bubendorf et al., 2000). The metastasis of prostate cancer affects “other organs 
such as liver, lungs etc” (Bubendorf et al., 2000). 
AR is a ligand-activated nuclear transcription factor known to play an important role in the direct 
regulation of gene expression along with its coregulators in normal and tumor types of prostate 
tissue (Sinnesael et al., 2012). The function of AR in normal prostate cells is to act as transcription 
factor that controls the expression of genes associated with physiological development such as 
differentiation and maturation of primary and secondary male sexual phenotype, male skeletal 
integrity and initiation and maintenance of spermatogenesis in males. The transcriptional activity 
of AR is activated through the binding of androgens; testosterone and dihydrotestosterone 
(DHT); by nuclear translocation. The transcriptional activity is in turn influenced by the interaction 
and phosphorylation of AR and coregulator factors (Roy AK1, Lavrovsky Y, Song CS, Chen S, Jung 
MH, Velu NK, Bi BY, 1998)(Srinivas-Shankar U, 2006). In prostate cancer, the cancer cells like the 
normal prostate cells need AR (undergoes post-translational mutation via acetylation) and its 
coregulators as they play a key role in the transactivation, growth and survival of the prostate 
cancer cells throughout the different stages of the cancer (Bardin CW, Brown T, Isomaa VV, 
1983)(Chang, 2016). One of the important aspects of AR is that it increases the ratio of cell growth 
proliferation and decreases the cell death (apoptosis), thus disrupting the normal cell 
proliferation-cell death ratio. The AR and androgen levels are also shown to be elevated in the 
cancer cells. The high levels of AR are maintained throughout the different stages of the cancer 
(Fu et al., 2002)(Denmeade SR, Lin XS, 1996). Hence, the blocking of androgens or the inhibition 
of the AR transcription factor by targeting the ligand-binding domain helps in the treatment of 
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the prostate cancer (Helsen et al., 2014). Thus, it is selected as primary drug target for anti-cancer 
therapy such as androgen deprivation therapy (ADT). However, recent studies have shown that 
prostate cancer have known to adapt and proliferate under androgen-deprived environment 
through the web of interactions between other transcription factors, oncogenes, tumor 
suppressor genes. It also leads to the abnormal reactivation of the AR (Rosa-Ribeiro et al., 
2014)(R. S. S. and K. E. Knudsen, 2013). 
 
The behavior of AR in the castrate-resistant prostate cancer (CRPC) is bit different from that of 
the commonly known prostate cancer. The varied nature of AR is caused to the formation of drug 
resistance to the anti-cancer therapeutic agents due to mutations such as gene amplifications 
(overexpression of AR as result of androgenic hormone suppression), gain-to-function mutations, 
alternate splicing, co-repressor loss of function and occurrence of intracrine androgen. Such 
mutations lead to uncontrolled cell-cycle progression and proliferation often leading to an 
incurable condition. This situation is often seen in about 10-20% of the treated patients 
(Eisermann, Wang, Jing, Pascal, & Wang, 2013)(Manuscript, 2011). 
However, the levels of AR in the primary stages of CRPC is low when compared to the later 
advanced stages. This leads to a possibility of other transcription factors that act as “master 
regulators” in place of AR and may also modulate with the high mutations of AR. These 
transcription factors help in maintaining the AR levels necessary for the growth and proliferation 
of cancer cells through coregulation or independently and may be overshadowed by AR in normal 
prostate cancer and quite prominent in CRPC. They could be selected as drug targets in addition 
to AR for treatment of prostate cancer. Understanding these genes helps in understanding the 
interactions of the signaling networks that primarily initiates the development of the variant 
prostate cancer and thus, opening the way for better therapeutic methods.  
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2. REVIEW OF LITERATURE 
 
Transcription factors are important protein molecules that regulate the rate of transcription of 
gene expressions; transfer of genetic data from target DNA to mRNA (messenger RNA) by binding 
to the specific complementary target DNA sequence; leading to all the biological and phenotype 
changes in all organisms (Latchman, 1993). There are around 2600 known TFs in the human 
genome that change the behavior of the target gene or cell by binding to their proximal or distal 
regulatory elements (Vaquerizas, Kummerfeld, Teichmann, & Luscombe, 2009). These process is 
important so that the specific gene is either turned “off” or “on”; downregulated or upregulated 
respectively; in order “to make sure that they are expressed in the right cell at the right time and 
in the right amount throughout the life of the cell and the organism”. TFs either act alone or 
coordinate together with other TFs and proteins to form complex molecules in order to “promote 
or repress” the activity of the RNA polymerase enzyme to the target genes  (Roeder, 1996) (Lee 
& Young, 2000). Transcription factors are of clinical significance because their activities; caused 
directly or indirectly; due to mutations could be associated with the development, cell signaling 
and cell cycle of specific diseases or disorders and hence potential drug targets such that acting 
on these specific TFs could help in regulating or combating the disease without affecting other 
important parts of humans and other organisms (Lee & Young, 2013). In association with cancer, 
TFs are either tumor suppressors (example: p53 gene) or oncogenes (example: HER2/neu gene) 
due to mutations or mis-regulatory activities (Dasgupta, Srinidhi, & Vishwanatha, 2012) (Zerbini, 
2006). Hence it is great importance to know as many details as possible of TFs regulatory network 
in diseases for better chances of clinical treatment.  
 
Androgens are sex hormones that are responsible for the development and the maintenance of 
the male sexual characteristics (development of primary sex organs and initiation of secondary 
sexual features at the onset of puberty). Testosterone and Dihydrotestosterone (DHT) are the 
main androgens present in males and mainly active in prostate cells.  Testosterone is produced 
in the Leydig cells in the testis and DHT is produced with the conversion of testosterone by the 
enzyme 5 alpha-reductase which enables DHT to bind to AR (Debes & Tindall, 2002) . The other 
function of androgen includes its role as “extracellular signals for the development as well as the 
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functional activity of the prostate epithelial cells” (Gao et al., 2003). The activities of androgens 
are regulated by the transcription factor, Androgen Receptor (AR). 
 
Androgen Receptor (AR) is a nuclear receptor and a ligand-regulated transcription factor that 
plays a critical role in the growth and development of male physiological characteristics 
particularly in the prostate gland development. AR gene is located on the X chromosome. It is 
expressed on prostate cells and on many tissues such as bones, muscles, adipose tissues, 
cardiovascular etc (Davey & Grossmann, 2016). AR is activated by binding to the male sex 
hormones, testosterone and dihydrotestosterone, in the cytoplasm. The binding causes the AR 
to undergo conformational change that initiates the dissociation of an inhibitory heat-shock 
protein complex and the translocation of AR complex to the nucleus and its consequent 
interactions for AR-target gene regulations with the help of multiple cofactors. Mutations in AR 
is one of the main contributor to the progression of prostate tumor (Jemal et al., 2006) (Norris et 
al., 2009). The mutated activation of these genes results in the progression of the prostate tumor 
cells and the metastasis of the prostate cancer. 
 
Many transcription factors and co-factors along with androgen receptor plays a major role in the 
development of prostate cells together with AR by taking part in the AR signaling process by 
enabling the opening of chromatin regions to allow RNA polymerase II to target gene promoters 
(Wang, Carroll, & Brown, 2005). A study of the reprogramming of the AR binding sites in the 
prostate tumorigenesis has shown that the transcription factors; FOXA1 and HOXB13; in 
cooperation with AR is relevant for the transformation of normal tissue to tumor in prostate 
cancer (Pomerantz MM, Li F, Takeda DY, Lenci R, Chonkar A, Chabot M, Cejas P, Vazquez F, Cook 
J, Shivdasani RA, Bowden M, Lis R, Hahn WC, Kantoff PW, Brown M, Loda M, Long HW, 2015).  
 
2.1. Androgen and Prostate Cancer (HDPC) 
 
Androgen Receptor is one of the main driving force behind prostate carcinogenesis. It is 
responsible for the proliferative, apoptotic and angiogenic mechanisms in the tumor cells. It has 
been proven that different cellular mechanisms and pathways influences prostate cancer growth 
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in an androgen-independent environment (Debes & Tindall, 2002). AR mediates the transcription 
of genes such as UBE2C and cyclin D by binding to the distinct DNA sequences that result in tumor 
proliferation (Xu, Chen, Ross, & Balk, 2006). Pioneer factors, for example FOXA1, enable the AR 
to interact with chromatin and in turn interact with coactivators and corepressors which either 
promote or repress transcription.  
 
AR is expressed in both Hormone-Dependent (HDPC) and Castrate-Resistant (CRPC) prostate 
cancers though it is present in low amounts in the primary stages of CRPC but increases its gene 
expression in the advanced metastasis stages. Prostate Cancer treatment focuses primarily on 
stopping the activity of androgen. An example consists of androgen deprivation therapy (ADT) by 
inhibiting the production of the androgens by “castration or using the use of androgen 
antagonists such as bicalutamide etc. Another example of treatment is surgical castration. 80% 
of the patients undergoing the treatment get cured from the tumor but there is a small chance 
that in the remaining 20% of the patients, the prostate tumor cells become unresponsive to the 
treatment and develop into hormone-independent prostate cancer when AR activity is slowly 
reactivated (K. E. Knudsen & Penning, 2010) (Xin Yuan & Balk, 2009) .  
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Figure 1: Visualization of Androgen Receptor interaction in the cancerous prostate cells of both Hormone-Dependent Prostate 
Cancer (HDPC, also known as Androgen dependent Prostate Cancer) and Castrate-Resistant Prostate Cancer (CRPC, also known 
as Androgen-Independent Prostate Cancer) (Nelson, De Marzo, & Isaacs, 2003) 
 
2.2. Castrate-Resistant Prostate Cancer (CRPC) 
 
AR is an important component of prostate cancer for its growth. The CRPC is the form of prostate 
cancer that arises when after the treatment methods like androgen deprivation therapy blocks 
AR transcription and cures the HDPC. CRPC adopts several alternative mechanisms for the tumor 
growth in absence or low expressions of androgens or AR. In CRPC, the AR is overexpressed 
through gene amplification (see Figure 1) or AR protein overexpression and allows the binding to 
chromatin structure in concentration lower than normal levels observed in normal prostate and 
HDPC (Carreira et al., 2014) (Urbanucci et al., 2011) (Cai et al., 2011). This initiates AR reactivation 
in the CRPC cells and enables the tumor cells to grow in low concentrations of AR.  Other 
mechanisms involve AR mutations such as gene/RNA splicing, intra-tumoral androgen synthesis 
(X Yuan et al., 2014), aberrant activation of AR without androgens and mutations of AR co-
regulators. AR splicing consists of expression of “C-terminal variants” called ARvs which are active 
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in mediating AR-regulated transcriptions and initiates tumor proliferation under castrate 
conditions (X. Zhang et al., 2011). In CRPC, AR follows a distinct transcription pathway different 
from the one in HDPC. It involves the direct activation, regulation and overexpression of genes 
related to M-phase of cell cycle “such as CDK1 and UBE2C” (Wang et al., 2009). This suggest an 
epigenetic reprogramming in CRPC in presence of low levels of AR and decrease of genes that are 
normally regulated by AR in normal and HDPC. This is the necessary driving force behind the need 
to find alternative treatment methods that do not depend on androgen and AR and hence, 
finding new potential drug targets. Successful targets are those that needs to be present in both 
forms of the prostate cancer and tend to follow same transcription program.  
 
2.3. Gene Expression Arrays 
 
Gene expression arrays or microarrays are one of the new technologic approaches available for 
modelling the expression profile of thousands of genes of interest in large amounts. This feature 
together with its “reproducibility of gene array studies” makes it of great practical importance in 
molecular biology research. More targeted gene arrays could be constructed for measuring small 
number of genes thus, increasing the specificity (Merker & Arber, 2010). Microarrays consist of 
collection of nucleic acids (DNA) attached to a solid surface such as glass slide or silicon surface 
and is used for detecting and measuring the expression level of target genes/nucleic acid 
sequences via probe hybridization. The nucleic acids present on the solid surface are called as 
probes which are either cDNA or oligonucleotides (Bumgarner, 2013).  
Microarrays produce high-quality data and are useful for monitoring gene expression levels to 
help researchers to study various biological questions such as; 
 Genetic interactions and study of molecular functions (Breitling, Amtmann, & Herzyk, 
2004), 
 Differential Expression studies 
 Genome Mapping 
 Mutations, 
 Disease classification and pathogenicity (Miklos & Maleszka, 2004),  
 Drug-Target response, 
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 Identification of new genes/variants (Shoemaker et al., 2001), 
 Construction and analysis of metabolic/signaling pathways (Roberts et al., 2000) 
 
Gene Expression Arrays or Microarrays depend on the manufacture of arrays, techniques 
implemented, probe selection, quantification of hybridization and data analysis for good 
reproducible results. Differentially expressed genes are detected using one- or two-color channel 
when comparing the experimental data with the reference sample. The channels are based on 
labelling the probes with fluorescent tags for identification and visualization of target genes to 
determine whether they are regulated positively or negatively (Liu, Bebu, & Li, 2010).  
 
The workflow of Microarray or Gene Expression Arrays involves the following; 
1. Extraction of RNA of target gene from biological sample, 
2. Conversion of RNA sample to cDNA with labelling through reverse transcription, 
3. Hybridization of the labeled cDNA to complementary probes, 
4. Removal of unhybridized cDNA, 
5. Detection and measuring expression levels of hybridized cDNA, 
6. Preparing the quantitative data for data analysis and comparison with other samples 
(“The Basics: What is a Gene Array?,” 2018) (Govindarajan, Duraiyan, Kaliyappan, & 
Palanisamy, 2012).   
 
2.4. Computational Analysis of Microarray Data 
 
Major biological breakthroughs such as the Human Genome Project helped us in reshaping our 
understanding of the genome of humans and other organisms. Many techniques were developed 
in analyzing this ever-growing biological data such microarrays to build gene expression patterns 
and metabolic networks based on cellular responses, phenotypes, sample conditions etc. 
(Quackenbush, 2001). Gene Expression Arrays produce enormous amounts of biological data and 
it cannot be directly interpreted due to the background differences, sample conditions, time 
points etc. Hence, processing the information is required and use of an algorithmic approach to 
make the data more understandable. The steps involved in the analysis are as follows;  
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 Data Preprocessing: This step, prior to analysis and result interpretation, involves the 
extraction of “meaningful” information from the gene expression data (raw data obtained 
from microarray) and its subsequent preparation for data analysis. Normalization, 
determination of spot intensities and background correction are some of the types of 
preprocessing (Tarca, Romero, & Draghici, 2006).  
 
 Filtering: Removal of non-variant genes/samples from the data. 
 
 Identification of differentially expressed genes (Loguinov, Mian, & Vulpe, 2004).  
 
 Classification or Class Prediction (Supervised learning): The approach allows the 
assignment of data to known classes using algorithms such as K-Nearest neighbor (kNN), 
Artificial Neural Network etc. This step involves training of the algorithm with the samples 
(training set) and testing of the algorithm on a separate group of samples (test set) 
(Selvaraj & Natarajan, 2011) 
 
 Clustering Methods (Unsupervised learning): The data analysis includes the discovery of 
new subgroups based genes/samples with common characteristics (Class Discovery) 
(Tarca et al., 2006).  Clustering is one such method that aims on grouping the “clustering 
of genes or samples with similar expression profiles or relationship” together based on 
distance/correlation measures to allow for meaningful interpretation of the data. 
Clustering methods are of two types: Hierarchical (based on relationships) or Non-
Hierarchical (not based on relationship). 
Hierarchical Clustering: the algorithm involves grouping together of small clusters of 
similar genes/samples within larger clusters of less-related genes/samples. It could be 
agglomerative (bottom-up approach where “each observation begins in its own clusters 
and merges with other clusters as it moves up the hierarchy”) or divisive (to-down 
approach where “all observations begin in one cluster and splits into other clusters as it 
moves down the hierarchy). Pairwise distance measures are used for calculating objects 
15 
 
into clusters and includes single linkage clustering, complete linkage clustering etc. (Babu, 
n.d.). 
Non-hierarchical Clustering: the algorithm involves determination the number of clusters 
required to be created and placing the observations with similar characteristics into those 
clusters. The two known types of non-hierarchical methods are K-means and SOM (Self 
Organizing Maps). 
K-Means Clustering: The objects are placed in predetermined number of clusters and the 
centroid for each cluster is calculated. The objects are rearranged from one cluster to 
another “depending on which centroid is closer to the object. The centroid calculation 
and rearrangement is performed in an “iterative manner for fixed number of times” or 
until no more rearrangements are possible.  
Self-Organizing Maps (SOM): The algorithm is similar in nature to K-means, but “the 
number and pattern of clusters” are selected with respect to each other. The SOM 
consists of a two-dimensional map or expression space filled with nodes (clusters). Each 
object is then moved to the node nearest to it. Next, a “random node is selected and the 
node in the locality of the object is moved closer to it”. “The other nodes are moved to a 
small extent depending on how they are to the selected object”.  The process in repeated 
with randomly selected objects, the node positions are refined, and the region of locality 
becomes confined. The map is “deformed” to fit the data. SOM does not force the clusters 
to be equal to the number of starting nodes. SOM can produce good results even with 
noisy data (Esa Alhoniemi, Jaakko Hollmén, 1996) (Babu, n.d.). 
 
 Result interpretation and data visualization (Loewe R.P., 2011).  
 
The data profiling enables the study of gene expression patterns, regulatory networks, metabolic 
pathways, disease progression or mutations (Zhang Y., Szustakowski J., 2009) (Hanai, Hamada, & 
Okamoto, 2006). Apart from data analysis, other factors are present which is what makes 
computational analysis of microarray data more essential. The factors include experimental 
design of data (complexity of the array data) (Churchill, 2002), annotation (Barbosa-Morais et al., 
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2010) and data storage. Many tools are available for microarray data analysis including 
Bioconductor project for the “comprehension of genomic data” based on R-Programming 
language. Hence, computational analysis is an important tool for biological researchers. The 
strategy for data analysis is determined by the purpose of the microarray experiment and 
biological question to be answered (Quackenbush, 2001). The results from the microarray 
analysis could be combined with other approaches to make new discoveries and information 
such as identification of transcription binding sites, protein-protein interaction 
networks/pathways, Gene set enrichment analysis (GSET) etc. (Selvaraj & Natarajan, 2011).  
 
In recent years, Gene Expression Arrays plays an important role in cancer research in the form of 
identification of pathways, oncogenes and new therapeutic targets, molecular diagnosis and 
genome mapping of the tumor sample to identify signaling molecules and other factors that aid 
in tumor growth and differentiation (Brentani et al., 2005). 
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3. AIMS & OBJECTIVES 
 
The aim of the study is focus on the data based on a previous research conducted on androgen 
regulation and to expand the scope, i.e., to identify and study the genes clusters that may contain 
transcription factors that may have important regulatory roles parallel to that of androgen 
receptor in the prostate cancer growth and survival.  
 
The objectives of the study are as follows: 
1) Download and process the data for analysis. 
2) Filtering out non-informative genes. 
3) Clustering of genes and detection of clusters with informative expression profiles (early 
up, early down, late up, late down, first up then down).  
4) Detection of transcription factors in the gene clusters that are relevant for prostate 
cancer. 
5) To identify transcription factors in early cluster groups that have the potential to regulate 
genes in the late cluster groups.  
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4. MATERIALS & METHODS 
 
The primary tool used in the extraction and analysis of the data is R programming and the 
bioconductor packages.  
 
4.1. GEO Dataset Source 
 
The data (accession number: GSE18684) for the analysis was obtained from Gene Expression 
Omnibus (GEO), an international public genomics data repository from National Center of 
Biotechnology Information (NCBI). GEO stores and allows free download of microarray data, 
next-generation sequencing and other types of genomic data sets. NCBI is a part of the United 
States National Library of Medicine (NLM) and provides access to various types of information 
related to biotechnological, health and biomedical fields. The data was downloaded using the 
GEOquery, a bioconductor package used in extracting data from GEO database (Massie et al., 
2011).  
 
4.2. Experimental Design of GEO Dataset 
 
The dataset includes the comprehensive analysis of “androgen regulated gene expression in 
LNCaP prostate cancer cell line”. LNCaP cells are androgen-sensitive prostate adenocarcinoma 
cells often used in prostate cancer research. The dataset was part of a study that was aimed to 
identify Androgen receptor (AR) regulated genes with the Illumina beadarray study of androgen 
regulated gene expression with AR ChIP-sequencing data. “The steroid-depleted growth medium 
in the ChIP analysis used for culture of LNCaP cells include the Roswell Park Memorial Institute 
(RPMI) medium which contains glucose, salts, amino acids, pH indicator and vitamins 
supplemented with 10% charcoal dextran stripped FBS for 72 hours prior to addition of 0.01% 
ethanol (vehicle control) or 1nM R1881 (treated). 1% formaldehyde was used for the cross-linking 
of DNA protein interactions for 10 minutes at room temperature and final addition of 125mM 
glycine for strengthening the interactions. 48 RNA samples were grown for 72 hours comprising 
of three groups: 3 time-zero samples, 10 ethanol (vehicle control) treated samples at 2h, 4h, 8h, 
12h and 24h with biological replicates, 36 R1881 (synthetic androgen) treated samples for every 
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30 minutes for 4h followed by every hour until 24h with biological replicates at 1h, 2h, 4h, 8h, 
12h, 16h, 20h and 24h. The RNA samples were extracted from ChIP using trizol and isopropanol 
preparation and quantification was performed using an Agilent Bioanalyser. Illumina TotalPrep 
RNA Amplification Kit was used in cRNA preparation and biotin labelling. Standard Illumina 
protocols were executed for hybridization and scanning procedures”.  
 
“The experiment involved in the construction of the target dataset used the Illumina HumanWG 
v2 BeadArrays. The array consists of two replicate sections that are treated as technical replicate 
arrays due to the small systematic shifts present between the sections that is addressed in the 
normalization resulting in 96 RNA samples. Data analysis was performed using beadarray 
software from the raw-bead level with the detection, automated removal (BASH) of spatial 
artefacts followed by manual curation. The dataset obtained as a result with reduced data was 
summarized with outliers removed to obtain a mean log-intensity and standard error for each 
probe/array combination. Probes that did not match to transcripts and those without any “signal 
above background” were removed. In the original study, a Biotrove Realtime PCR was used to 
confirm the AR binding sites and gene expression changes using primers, SYBRgreen chemistry 
(Applied Biosystems, 2x SYBRgreen master mix) in an ABI7900 instrument. The final dataset 
consists of 17182 probes” (Massie et al., 2011).  
 
4.3. Autocorrelation Method to Filter Probes 
 
The study involved in the mapping of the androgen regulated genes and construction of GEO 
dataset used autocorrelation at lag 1 was used as a measure to detect probes that showed a 
systematic smooth change over time without prescribing a form for that change. Autocorrelation 
is the “correlation of a time series with lags of itself”. It shows how the previous state/condition 
(lagged observations) has an influence on the current state/condition.  If the autocorrelation 
crosses a certain threshold it means that the specific lag is significantly correlated with the 
current state. It is also used to determine if the given time series is stationary or not depending 
on whether the value becomes zero quickly or gradually respectively. Autocorrelation in the 
analysis was used to identify probes where the “neighboring time-points” are more 
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homogeneous than the heterogeneous time points. This allowed the identification of probes that 
showed all smooth and systematic gene expression changes irrespective of the shapes of the 
expression profiles. 100 sets of observations were simulated from the known means and 
standard errors to calculate the autocorrelation and mean of each set, considering the variability 
in the measurements (Taylor, 1990).  In the experiment, a cut-off value of 0.5 was suggested to 
have low false-discovery rate. The same cut-off value was used in the filtering of probes that 
showed androgen response that have > 0.5 to obtain the desired set of clusters that show the 
desired expression information profiles. Thus, resultant dataset consisted of 3687 probes (Massie 
et al., 2011).  
 
4.4. R Programming & Bioconductor Project 
 
R is a special programming language and free computational system for “statistical computing 
and graphics”. It consists of a run-time environment with “graphics, a debugger, access to certain 
system functions and able to run programs stored in script files”. The fundamental behind R is an 
“interpreted computer language “which allows branching, looping and modular algorithms using 
functions. R consists of functionality for many statistical procedures which “includes linear and 
generalized linear models, non-linear regression models, time-series analysis, classical 
parametric and nonparametric tests, clustering, smoothing and a flexible graphical environment 
for the implementation of data presentations. Special Add-on packages are available for 
additional distinct functions. R is widely used for statistical analysis, scientific computation, 
visualization and data mining. R is developed for Unix-based, Macs and Windows operating 
systems. R is available as a free software with command line interface distributed under GNU 
General Public License and its source code is a part of the GNU project (R Core Team, 2018). R is 
also available as several graphical user interfaces such as Integrated development environment 
and RStudio (Leonard, 2013).  
 
Bioconductor Project is an open source development software which provides tools “for the 
analysis and comprehension of high-throughput genomic data. It follows the R programming 
language. It also includes meta-data packages consisting of pathways, organisms, microarray and 
21 
 
other annotations”. Its packages also include “the analysis of DNA microarray, sequence, flow, 
SNP, and other data”. There are approximately 934 packages available. It was started in 2001 and 
is maintained by several international institutions (Huber et al., 2015) (Gentleman et al., 2004) .  
 
R and Bioconductor project which consists of packages for analyzing biological data is used 
extensively and considered fundamental by computational biologists for research. “The rich set 
of inbuilt functions enables for high-volume analysis, statistical simulations and high-quality 
graphical output at all levels of the research within R along with development of ideas for 
answering biological questions”. In addition, “the packaging system” also makes it ideal for codes 
to be shared (Gentleman et al., 2004) (Eglen, 2009).   
 
R programming with packages from Bioconductor project was used for the analysis of the 
microarray data. R was used for data preprocessing, gene filtering, clustering, extraction and 
identification of transcription factors. Some of the prominent bioconductor packages used in this 
study include Genefilter, ggplot2 and illuminaHumanv2.db. 
 
4.4.1. Genefilter Package 
 
A Bioconductor package consisting of methods for filtering genes from high-throughput 
experiments. Variance-based filtering (var.filter) was used to remove genes with low or no 
variance from the gene expression data (R. Gentleman, V. Carey, 2018). A variance cut-off value 
(var.cutoff) of 0.1 was used, based on multiple runs, to obtain the 3318 probes that matches 
approximately with the number of probes obtained in the original study.  
 
4.4.2. ggplot2 Package 
 
The ggplot2 package enables R to visualize the extracted information from the data for better 
understanding in form of line plots, scattered plots etc. It creates “publication-quality statistical 
graphics in an efficient, elegant, organized and coordinated manner” (Ito & Murphy, 2013).  
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4.4.2. illuminaHumanv2.db Package 
 
The illuminaHumanv2.db is an annotation package used for mapping genes to specific features 
of interest to identify the nature of the data and is also used as means for purging data that do 
not have annotation during data preprocessing (Mark Dunning, 2015).  
 
4.5. Data Preprocessing  
 
The time-series experimental data was preprocessed by removing the biological replicates by 
using average means. Normalization is conducted by dividing the time-series sample with zero-
time value and filtering of the data for non-variant genes was performed using autocorrelation 
and Genefilter package. The probes were annotated using illumina package 
(illuminaHumanv2.db) 
 
4.6. K-Means Clustering 
 
K-means clustering is a type of the unsupervised learning cluster technique that classifies 
together undefined data into K-clusters. Each data point of a given data set is assigned to one of 
the K-cluster/groups based on feature similarity; i.e. each data point in each cluster are closer to 
each other than to data points in other clusters. The centroid of each cluster is a collection of 
features which define the characteristics of each K cluster and each centroid is placed away from 
each other as much as possible. The data points are associated with each nearest centroid based 
on feature values and is completed when no more points are present. The number of k-clusters 
in this study is 14 which is determined after multiple simulations, final number of probes, and 
finally to reduce unwanted and less significant clusters to save time taken in the analysis. The 
“ggplot” package was used to line plot the k-clusters to identify prominent k-clusters based on 
the information profile determined in the original study.  
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4.7. ENCODE ChIP-Seq Significance Tool 
 
ENCODE ChIP-Seq Significance Tool is a simple flexible web application that helps to analyze and 
identify “enriched ENCODE transcription factors from a list of genes of transcripts” by comparing 
with public ENCODE data. It is one of the tools that helps in analyzing data related to biological 
processes and phenotype expression.  The significant features of the tool include as follows; 
 Entering multiple gene or transcript lists at a time, thus reducing the analysis time and 
less errors when rerunning the tool multiple times. The results are displayed alongside 
their respective lists in the same table for easy comparison. 
 Entering own custom-made list of background genes or transcripts and be used to search 
for gene or transcript lists extracted from “expression microarrays, next-generation 
sequencing strategies with array-capture methods and assays that do not search entire 
genome/transcriptome”.  
 Any value between 500-5000 base pairs could be selected in the analysis window in either 
upstream or downstream direction. 
 Customization of the analysis to create more understanding of biological processes like 
the usage of either the whole gene/transcript body, TSS, TTS as the center of analysis 
window.  
The objective of the online tool is to provide more flexibility to run the analysis to suit the 
methodology and on answering wide range of biological questions without been held back by 
limitations including no limits in the addition of TFs and cell treatment combinations. It also helps 
in exploring the potentiality in either TSS or TTS sites.  
This tool enables the identification of enriched TFs from one or multiple gene lists. “Transcription 
binding significance” is calculated using hypergeometric test followed by multiple hypothesis 
correction using Benjamini and Hochberg (False Discovery Rate - FDR) method. THE FDR method 
involves the identifying the rate of type I errors in null hypothesis in multiple comparisons and 
controlling the expected proportion of incorrect discoveries. A minimum false discovery rate is 
calculated as the q-value to define a transcription factor (< 0.05) as significant.  
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4.7.1. Hypergeometric Test 
 
Hypergeometric distribution is a discrete probability distribution that describes “the probability 
of successes in random draws without replacement from a finite population of given size 
containing the objects with specific features in which each draw is either a success or a failure. 
This is the exact opposite of binomial distribution in which describes probability of success in 
draws with replacement”. The Hypergeometric Test uses this distribution to calculate the 
statistical significance to identify which “sub-populations are over- or under- represented in a 
sample”. The result of each draw is classified into one of the two mutually exclusive categories 
and the probability of a success changes with each draw as the population decreases (without 
replacement).  
The formula for calculating the hypergeometric distribution is given as follows (Rice, 2007); 
 
where; 
N - the size of the population  
K - the number of success in a given population 
k - the number of observed success  
n - the number of draws 
P - The probability of obtaining k successes 
 
- The number of combinations of K success taken k at a time 
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4.8. TRRUST 
 
Development of “genome-scale regulatory circuit models” remain hindered due to the lack of all 
the information of the “intrinsic complexities of the human transcriptional networks” and due to 
technical limitations in genome mapping of such networks. Experimental procedures such as ChIP 
(chromatin immunoprecipitation) and genome sequencing analysis coordinated with together 
with research literature of cellular context helps in constructing, combining and understanding 
the complex TFs-target gene interactions on a genome scale.  
TRRUST (Transcriptional regulatory relationships unraveled by sentence-based text mining) is a 
manually curated database of human and mouse TF-target regulatory interactions. A sentence-
based text mining approach is used over Medline abstract for by extracting text sentences that 
is associated with transcriptional regulation and subjected to manual curation. There are around 
8,444 TFs-target gene interactions and is currently one of the largest known public database of 
“literature-curated TFs regulatory interactions” to date. The significance features of the TRRUST 
database is as follows; 
 It has annotations for mode-of-regulation in many known interactions. 
 It can perform a “network analysis” of TFs-target genes interactions by incorporating 
functional or physical protein interaction networks to provide “various systemic context 
information for facilitating functional interpretations such as target modularity, TF 
cooperativity and TF-pathway/disease associations”.  
 High enrichment of gene-pairs in top-ranked regulatory interactions inferred from high-
throughput expression data.  
All these features point out on how TRRUST could become an important benchmark for 
construction and study of complex transcriptional regulatory networks (Han et al., 2018).  
In this study, this tool was used for finding transcription factors that have ability to interact and 
regulate target genes of late clusters (up-late and down-late information profile). Final identified 
TFs will be crosschecked with the TFs of early clusters for final verification.   
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5. RESULTS 
5.1. Primary Objective 
 
14 primary clusters were obtained from the K-cluster analysis using R programming. From the 
primary set of clusters, 10 clusters were further selected based on the information profile 
obtained from the plotting of these secondary clusters using “ggplot2”.  The information profile 
of the selected clusters correlated with the desired information profiles obtained in the original 
research (Massie et al., 2011). The information profiles of the original study are based on the 
gene expression changes and were divided into two groups - up and down - based on gene 
response to androgen stimulation and further subdivided into two more groups - early (4.5 hrs) 
and late (4.5 hrs) – based on the response time (see Figure 2). These information profiles are 
considered as primary in this study. In addition, two more groups were constructed to pattern 
other gene expression changes – first up then down and first down then up. The two new groups 
were not present in the original study and are referred in this study as secondary information 
profile. Also, the “no androgen” stimulation from the original study was not considered for 
present study.  
 
From the second group of 10 selected clusters, the gene list of each cluster is collected and given 
as input for the online tool – ENCODE ChIP-Seq Significance Tool. This tool enables the 
identification of transcription factors using False Discovery Rate Method. The following 
parameters were used for running the algorithm;  
 Human genome reference - Hg19 
 Regulatory elements - Protein-Coding Genes is selected for analysis 
 Feature Information - Gene Symbol (Input is presented in the form of gene symbol list) 
 Background Regions - Default option of using all genes/transcript that have the selected 
ID type as a population for hypergeometric test. 
 Analysis Window Parameters - TSS of 5-prime end of the target genes is selected as the 
center of analysis window. The size of analysis window in base pairs (bp) in both upstream 
and downstream was selected to be 2000 bp. The reason for selecting 2000 bp is because  
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  
 Figure 2: Visualization of the gene expression data under androgen stimulation of the 6 clusters with the following 
information profiles: A) Up-Early, B) Up-Late, C) Down-Early, D) Down-Late, E) First Up then Down and F) First Down 
then Up. Figures 2-A, B, C, D represent primary/linear information profiles while Figures 2-E, F represent secondary 
information profiles.  
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it has been previously been studied that around 8.5-12.6% of AR binding sites were 
mapped in within 2kb of TSS (Cheng et al., 2015).  
 Cell Lines - Default option of all cell lines since no other suitable ones were available in 
the given options.  
 
From the output, six out of ten clusters have been identified to interact with several transcription 
factors (See Figure 2). These clusters also showed the information profiles as expected: up-early, 
up-late, down-up, down-late, first up then down and first down then up. 
 
First focusing on the 4 clusters with primary information profiles. The first cluster (Up-Early 
profile) has identified 145 TFs, the second cluster (Up-Late profile) has 179 TFs having the highest 
number among the clusters while the third cluster (Down-Early profile) has 62 TFs with the lowest 
number, and finally, the fourth cluster (Down-Late profile) has 173 TFs. About 33 transcription 
factors were identified to be common between all the 4 clusters; HMGN3, PHF8, SIN3A, TBP, 
CCNT2, E2F6, POL2, MAZ, ELF1, CFOS, CREB1, E2F1, CHD2, NRSF, TAF1, MXI1, ZBTB7A, RBBP5, 
YY1, MAX, E2F4, SP1, CoREST, CMYC, EGR1, UBTF, GATA3, FOXA1, SMC3, USF1, ZNF143, HNF4A 
and BACH1.    
 
In the case of final two clusters with secondary information profiles. The first cluster (First Up-
Then Down profile) has identified 24 TFs followed by the second cluster (First Down-Then Up 
profile) has 79 TFs. About 12 transcription factors were identified to be common in both the 
clusters; POL2, ZNF263, MAZ, CTCF, RAD21, MAX, EGR1, SIN3A, TAF1, GATA3, YY1 and E2F1.  
 
Overall, 8 transcription factors that are common to all clusters were selected due to potential 
ability to influence the prostate tumor growth and progression. The TFs selected are; POL2, MAZ, 
CTCF, EGR1, SIN3A, TAF1, GATA3, YY1 and E2F1. Pol2 (RNA Polymerase II) enzyme plays a key 
role in DNA transcription for almost all the genes and hence is not suitable for potential drug 
target in terms of specificity. MAX gene was chosen not to be discussed further due to lack of 
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information to support its role and effect in prostrate tumor. All these transcription factors have 
shown to have good significant Q-value in the ENCODE Chip-Seq Significance Tool.  
Also, three additional TFs were selected; two from the cluster sets of primary information profile 
and one from cluster sets of secondary information profile. The TFs selected are FOXA1, SP1 and 
CTCF. The reason for selecting these TFs is because of their previously known relationship to 
androgen receptor and prostate cancer development. Another reason is due to presence or 
absence in the cluster sets. On one hand, FOXA1 and SP1 are shown to be active in the cluster 
sets of primary information profile while they are inactive in cluster sets of secondary information 
profile. On the other hand, CTCF is active in the cluster sets of secondary information profiles 
while it is inactive in the cluster sets of the primary information profiles. Both CTCF and FOXA1 
are pioneer factors. Pioneer factors are transcription factors that directly bind to chromatin, thus 
remodeling the chromatin to exert positive or negative regulatory control on transcription by 
recruiting other TFs, directing histone modification enzymes on target gene enhancer or 
promoter region and influencing DNA methylation (Cirillo et al., 2002). 
 
5.2. Secondary Objective 
 
TRRUST was used in identifying transcription factors present in early cluster group (Up-Early & 
Down-Early profiles) that have the potential to regulate the expression of target genes in the late 
cluster groups (Up-Late & Down-Early profiles) (Han et al., 2018). The list of target genes of late 
clusters was used as input. The text-mining algorithm obtain the list of transcription factors that 
have regulatory relationship with the target genes. 13 TFs were found to interact with the query 
genes of Up-Late cluster (see Figure 3) while 28 TFs were found to interact with the query genes 
of Down-Late cluster. The TFs are then compared with the TFs of the early clusters obtained in 
the analysis of the primary objective to find positive matches. The TFs found are CTCF, YY1, USF1, 
E2F1, BRCA1, HDAC1, STAT1, SP1 and EGR1. Among them, YY1 is seen to be of great potential as 
it is present in both the late clusters and due to its multifunctional nature.  
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Figure 3: List of transcription factors obtained by text-mining algorithm in TRRUST for gene expression data corresponding to Late 
Cluster Group (Up-Late Information Profile) 
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6. DISCUSSION 
The nature and relationship of identified TFs of significance with AR in prostate cancer is 
explained below; 
 
6.1. Transcription Factors of Interest 
 
6.1.1. TAF1 
Gene Location: Chromosome X, Band: Xq13.1 
TAF1 (TATA binding protein-associated factor 1) is a protein-coding gene that joins with the 
transcription factor, TBP (TATA binding protein), to form the transcription factor complex known 
as TFIID (Transcription Factor II D) which in turn is a part of the preinitiation complex of RNA 
polymerase II. This complex is important for the “coordination of the 70 polypeptides for the 
initiation of transcription by RNA polymerase II”(Louder et al., 2016). TAF1 and also other 
members of TAF family initiate “activator-dependent transcription in a promoter and tissue 
specific manner” (Martel, Brown, & Berk, 2002). TAF1 gene is present on the q-arm of 
chromosome X and its protein has the special function(s) to act as protein kinase & histone 
acetyltransferase, mediate ubiquitin-activation/conjugation and phosphorylation in cells. 
(Dikstein, Ruppert, & Tjian, 1996) (Mizzen et al., 1996) (Pham & Sauer, 2000) . TAF1 was reported 
to interact and coactivate with AR in prostate cancer cells. On one hand, it represses the 
transactivation of AR leading to significant decrease in AR levels in the tumor cells while, on the 
other hand, it increases the transcriptional activity of AR by many levels by controlling c-Jun, 
MDM2 and cyclin D1 (Cai, Hsieh, & Shemshedini, 2007) (Gaughan, Logan, Neal, & Robson, 2005) 
(Narayanan, Narayanan, Davis, & Nargi, 2006). The overexpression of TAF1  in CRPC is necessary 
for the survival and growth of the CRPC by reducing or even ubiquitinate AR in order to prevent 
the potential targeting by drugs unlike its predecessor form, thus its crucial role (Peyman 
Tavassoli et al., 2010).   
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6.1.2. SIN3A 
Gene Location: Chromosome 15, Band: 15q24.1 
SIN3A is transcription factor with paired amphipathic helix domains necessary for protein-protein 
interactions (Yu, Thiesen, & Strätling, 2000). It belongs to a corepressor family of Sin3 proteins 
which are known for mediating the gene expression for the downregulation of transcription 
activity of many genes (Halleck et al., 1995). Previous research has shown that SIN3A acts as a 
component of transcription repression complexes and acts as a pathway for interaction between 
DNA repressors and HDAC (histone deacetylase) enzymes. An example includes the studies 
showing SIN3A interacting with its corepressors EBP1 and TGIF and in turn enhances the 
functional ability of both genes (Y. Zhang, Akinmade, & Hamburger, 2005) (Sharma & Sun, 2001). 
Both the complexes have known to inhibit the transcription of other factors like E2F1 and AR-
regulated genes. Thus, SIN3A on an overall scale, is repressor of the prostate cancer growth and 
differentiation. In castrate-resistant prostate cancer (CRPC), SIN3A-EBP1-HDAC complex reduces 
the expression of AR and its target genes by decreasing the protein translation of AR. Hence, the 
exact mechanism is not known. In HDPC, the complex downregulates both by destabilizing mRNA 
of Androgen Receptor (AR) and stops its protein translation (Zhou, Zhang, & W Hamburger, 
2011).  
 
6.1.3. MAZ 
Gene Location: Chromosome 16, Band: 16p11.2 
MAZ (MYC-Associated Zinc Finger Protein) is a transcription factor that plays an important role 
in the development and survival of many types of cancers by controlling the upregulation of the 
gene expression of oncogenes. In prostate cancer, studies have shown that MAZ expression 
shows positive correlation with AR expression and in higher concentration in prostate tumor 
samples (W. Luo et al., 2016).  The MAZ knockdown by siRNA (small interfering RNA) lead to the 
inhibition of cell growth, proliferation and arresting of cell cycle. It also resulted in the breakdown 
of the metastasis and differentiation of the cancer cells. Another interesting factor presented in 
the study was that when AR was knockdown by siRNA, MAZ expression decreased a bit but when 
MAZ knockdown occurred, AR expression levels increased. This showed the connection between 
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MAZ and AR. MAZ was selected as potential drug target in castrate-resistant prostate cancer 
(Shen, 2013).  
 
6.1.4. YY1 
Gene Location: Chromosome 14, Band: 14q32.2 
YY1 (Yin Yang 1) is a transcription factor that has dual properties as both activator and repressor 
of many promoters by directing histone modification in both normal and cancer cells (Inouye & 
Seto, 1994). YY1 has been known to take part in regulation of genes by acting as co-factor to 
proteins that take part in cell proliferation, embryonic development, tumor mutation and 
apoptosis (Sui, 2009) (J. Luo et al., 2013). Upregulation of YY1 leads to disturbing the effects of 
its target gene and influences tumorigenesis. From in-vitro protein studies and 
immunoprecipitation analysis, YY1 has been reported to interact with AR and optimizes the 
transcription activity of AR in normal cells (Z. Deng et al., 2009) but the overexpression of YY1 in 
prostate cancer cells mainly downregulates AR and its cofactors by interfering the formation of 
the transcription complex and the subsequent “inverse effect” on target genes of AR regulation 
(Kashyap & Bonavida, 2014). But YY1 also has a slight positive effect on AR regulation; by 
suppressing the transcriptional activity of HOXB13 which is responsible for arresting the cell 
growth in AR-mediated tumor proliferation; by forming a complex with Histone deacetylase 4 
(HDAC4) which in turn binds to the two YY1-binding sites present on HOXB13 promotor (Ren et 
al., 2009). YY1 also plays an important role in the initiation of five transcription-factor regulated 
signaling networks along with p53, AR, c-MYC and SP1 in both normal and prostate tumor (Sun 
et al., 2008).  YY1 also regulates the transcription of miRNAs (MicroRNAs). In turn as key 
regulators, miRNAs influence many biological processes and act as tumor suppressors. Excess 
levels of miRNAs mediate prostate cancer cells “in terms of apoptosis, progression and viability 
by directly targeting the EGFR, RAC1, ROCK1, interleukin-1 receptor-associated kinase 1, and 
tumor necrosis factor-associated factor 6”. YY1 downregulates the transcriptional activity of 
miRNA in cancer cells. This was proven in a study by downregulation YY1 and promoting miRNA 
activity  (Huang et al., 2017). It has been proven that the processes exerted by YY1 activity are 
reversible in nature. The overexpression of YY1 upregulates the AR transcriptional activity in 
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CRPC to its pre-treated levels. Hence, YY1 has been discovered to a potential drug target in cancer 
treatment (Sui, 2009) (Zhiyong Deng, Cao, Wan, & Sui, 2010).  
 
6.1.5. EGR1 
Gene Location: Chromosome 5, Band: 5q31.2 
EGR1 (Early Growth Response-1) is a transcriptional regulator associated with the activation of 
cell differentiation and mitosis trigger (Guerquin et al., 2013) (Zwang et al., 2011). In prostate 
cancer, EGR1 has the dual role of both suppressing and progressing tumorigenesis. It is involved 
in apoptosis and cell growth. EGR1 is present in high concentration (Thigpen et al., 1996) in the 
tumor cells than in normal cells due to the mutational loss of its repressor NAB2 (Abdulkadir et 
al., 2001) or mutation of B-RAF gene (Davies et al., 2002).  In a hormone-dependent environment, 
EGR1 interacts with cascading to a series of events from AR translocation to nucleus, transcription 
of PSA (Prostate-Specific Antigen) and finally to tumor proliferation (S. Yang, 2003). In hormone-
independent situation, EGR1 in overexpressed levels enhances the prostate cell growth by 
interacting with the low AR levels and downregulating AR target genes (Mulholland et al., 2011) 
(S.-Z. Yang, Eltoum, & Abdulkadir, 2005). Inhibition of EGR1 leads to blocking the metastasis of 
tumor cells (Mulholland et al., 2011). Hence EGR1 is a potential target for anti-cancer therapy.   
 
6.1.6. E2F1 
Gene Location: Chromosome 20, Band: 20q11.22 
E2F1 was present in all the clusters ranging from low to high significant levels. E2F1 plays a key 
role in the” driving S-phase of the cell cycle during cellular proliferation” (Engelmann & Pützer, 
2012). The effect of E2F1 in CRPC includes the downregulation of AR factor in prostate cancer 
cells which is associated with the tumor development (Davis et al., 2006). In a previous study, 
significant increases in E2F1 expression with its gene regulatory signatures were detected in the 
“metastatic prostate cancer tissue microarray”. Though E2F1 downregulates AR expression, it 
drives the prostate cancer progression and metastasis by mediating target genes like DNMT1 
gene (McCabe et al., 2006). E2F1-DNMT1 complex contributes to the metastasis by “epigenetic 
silencing of tumor suppressor genes (Valdez, Kunju, Daignault, Wojno, & Day, 2013).  
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6.1.7. GATA3 
Gene Location: Chromosome 10, Band: 10p14 
GATA3 is a transcription factor encoded by the GATA3 gene which is located on the p14 of 
chromosome 10. It is responsible for the regulation of expression of known relevant genes 
(Yamashita et al., 2004), particularly the physiological and pathological immune responses and 
embryonic development of varied tissues (Barnes, 2018). It is important in cancer studies as an 
important clinical marker of known cancers particularly breast cancer (Ordóñez, 2013). The 
GATA3 gene codes for two variant transcripts – GATA3 variant 1 and GATA3 variant 2. There are 
no reported studies related to the differences between the variants. Both variants are taken into 
consideration in the clinically studies and laboratory research. All members of GATA transcription 
factors are essential in the primary stages of prostate cancer development particularly, GATA2 
and GATA3 which has shown interactions with AR signaling both in coordination, correlation and 
regulation of gene expression. However, the removal of GATA transcription factors did not cause 
decrease in AR-related expression levels but instead increased tumor progression(Nguyen et al., 
2013). This shows that these TFs do not actively participate in all the stages of the tumor growth 
(Xiao et al., 2016).  
 
In all the final clusters, GATA3 is present in all in significant elevated levels. GATA3 is shown to 
be integral in AR signaling in low risk type breast cancer (Sanga, Broom, Cristini, & Edgerton, 
2009). A study has shown that both GATA3 and AR show high correlation in breast cancer. A 
“unique high level of correlation” between the two TFs (95% confidence interval) compared to 
other correlations studied. It has also shown that “strong AR expression” levels in lobular and 
urothelial carcinoma is reported as excellent detection tool for identifying GATA3+ rich setting 
(Boto & Harigopal, 2018) (Kim et al., 2016). In prostate cancer, GATA3 could plays a more 
influential role . As explained before, GATA3 is not active in tumor development but in CRPC its 
role potentially become more prominent. The strong correlation could suggest that GATA3 could 
potentially be one of the primary factors responsible for the growth and progression of tumor in 
presence of low level of AR in primary stages of CRPC before the AR levels increase to levels found 
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in hormone-dependent prostate cancer. Another evidence of GATA3 involvement in CRPC is its 
interaction with transcription factor regulator – FOXA1, which is considered to be one of 
important factors involved in the initiation and progression of prostate cancer together with AR 
and HOXB13 (Pomerantz MM, Li F, Takeda DY, Lenci R, Chonkar A, Chabot M, Cejas P, Vazquez F, 
Cook J, Shivdasani RA, Bowden M, Lis R, Hahn WC, Kantoff PW, Brown M, Loda M, Long HW, 
2015) (Albergaria et al., 2009).   
The presence of GATA3 in all the clusters and the evidence of its correlation with AR suggest 
strongly GATA3 could take the role of AR in the initial stages. Further studies are required in fully 
mapping out the role and specific function of GATA3 in both the primary stages of hormone-
dependent prostate cancer (PCA) and castrate-resistant prostate cancer (CRPC).  
 
6.2. Other Significant TFs  
 
6.2.1. FOXA1 
Gene Location: Chromosome 14, Band: 14q21.1 
FOXA1 is a transcription factor that is primarily act as pioneer factor. FOXA1 (also known as 
forkhead box A1) by opening chromatin on the target DNA and mediates the passage of other 
transcription factors like Androgen Receptor (AR) to bind to its target sequence (Augello, Hickey, 
& Knudsen, 2011) (Sahu et al., 2011). It is also due to its pioneering trait that it is essential in the 
early development processes such as embryonic growth, initiation of “tissue-specific gene 
expression and regulation of gene expression in differentiated tissues” (Lupien et al., 2008). Thus, 
FOXA1 is essential in prostate growth and differentiation due to its important role in the AR 
activation and regulation of the target genes (Wang et al., 2007) (Gao et al., 2003). FOXA1 
expression in prostate cancer are high compared to the normal prostate cells particularly in the 
CRPC (Gerhardt et al., 2012). A study has shown that FOXA1 regulates AR variants such that the 
knockdown of FOXA1 results in the reduction of tumor cell growth and thus the activity of AR and 
its variants. Hence, FOXA1 could be a potential drug target for cancer therapy (Jones et al., 2015).  
 
37 
 
But in this study, FOXA1 is not active all the time and probably under certain conditions, is not 
the prime pioneering factor which is instead replaced by CTCF as seen in the clusters of secondary 
information profile. This is supported by the fact that other studies had detected low levels of 
FOXA1 expression in CRPC tumors (Jin, Zhao, Ogden, Bergan, & Yu, 2013). 
 
6.2.2. SP1 
Gene Location: Chromosome 12, Band: 12q13.12 
SP1 are proteins of zinc-finger family that mediates an important role in many cellular processes 
in both normal and tumor cells. SP1 is present in high concentrations in many cancers including 
prostate cancer and is used as cancer marker. SP1 binds to the GC rich domain in the promoter 
region of target genes. It regulates a range of target genes that are “involved in cell cycle, 
proliferation, cell growth and proliferation and apoptosis. These genes include AR, TGF-Beta, C- 
MET, PSA, TFIID, TBP, NF-kB etc. These features make SP1 an important therapeutic target by 
blocking its interactions in prostate cancer (H. Yuan, Gong, & Young, 2005) (T Sankpal, Goodison, 
Abdelrahim, & Basha, 2011).  
In CRPC, SP1 is overexpressed. It is also found to be correlated with the PKM2 (pyruvate kinase 
isoenzyme type M2). PKM2 is a glycolytic enzyme that plays a key role in tumor metabolism and 
survival. PKM2 helps the cancer cells to obtain nutrients required for growth and proliferation. 
Additionally, PKM2 also plays as an “activator and protein kinase” in tumors (Dong et al., 2016). 
SP1 directly regulates PKM2 and in turn SP1 controls metabolism, growth and autophagy. SP1-
PKM2 pathway is repressed by tumor suppressor miRNAs and focusing on this interaction is of 
great clinical significance for prostate cancer treatment (Ling et al., 2017). 
 
6.1.3. CTCF 
Gene Location: Chromosome 16, Band: 16q22.1 
CTCF (also known as 11-zinc finger protein or CCCTC-binding factor) is a transcriptional repressor 
and a pioneer factor like FOXA1. The primary role of CTCF involves chromatin structure 
remodeling to form chromatin loops on binding to target DNA. The CTCF-DNA complex then 
anchors the DNA to the cells and regulates the expression of genes. CTCF also acts as barrier for 
38 
 
the interaction between enhancers and promoters (Phillips & Corces, 2009). Depending on the 
histone modification enzymes it binds to, it could act as either an activator or repressor. “When 
the CTCF complex binds to histone acetyltransferase (HAT), it becomes a transcriptional activator 
and when the complex binds to histone deacetylase (HDAC), it becomes a transcriptional 
repressor”(“Cancer Genetics Web - CTCF,” n.d.). In this study, CTCF has shown to be active under 
certain conditions in the tumor progression as seen in the data of primary information profile.  
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7. CONCLUSION 
 
From the analytical results and evidence from previous studies, GATA3 is the most potential 
candidate for drug target in CRPC followed by YY1 and SP1. The latter two have already been 
proved to potential drug targets in previous studies.  
Further analysis is required for considering GATA3 as a drug target. To strengthen this hypothesis, 
a similar approach and methodology is required by applying on a HDPC-based dataset to detect 
low levels of GATA3 when AR levels are high as a template for comparison with CRPC. Also, it is 
important to further study the presence, response and stimulation of GATA3 in CRPC and how 
exactly it does contribute to androgen-independent prostate cancer growth and progression to 
metastasis before its loss of active role.  
 
8. LIMITATIONS 
 
The limitations associated with this analysis is as follows; 
 The identified transcription factors; alternative to Androgen Receptor (AR); are based on 
interpretation of the analytical results and is limited due to the incomplete understanding 
of the genomic network of castrate-resistant prostate cancer, possible variability of 
phenotype expression/mutations in tumor samples across individuals etc.  
 To obtain hormone-dependent prostate cancer (HDPC) dataset of similar nature to the 
CRPC dataset used in both the original and current analysis to support the hypothesis of 
GATA3 activity and its relationship to AR in prostate cancer of both types. 
 The exact significance of GATA3 in prostate cancer in order further understand its 
regulatory role in prostate cancer in both androgen-dependent and -independent 
environment is much less understood and poorly studied. Hence, more studies are 
required in this direction.  
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